Page last updated: 2024-09-03

rasagiline and Multiple System Atrophy Syndrome

rasagiline has been researched along with Multiple System Atrophy Syndrome in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abler, V; Goebel, G; Krismer, F; Papapetropoulos, S; Poewe, W; Schocke, M; Seppi, K; Wenning, GK1
Galpern, WR1
Barone, P; Eyal, E; Fitzer-Attas, CJ; Giladi, N; Gilman, S; Low, PA; Poewe, W; Rascol, O; Sampaio, C; Seppi, K; Wenning, GK1
Abler, V; Krismer, F; Papapetropoulos, S; Poewe, W; Seppi, K; Wenning, GK1
Poewe, W; Stefanova, N; Wenning, GK1

Trials

3 trial(s) available for rasagiline and Multiple System Atrophy Syndrome

ArticleYear
Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy.
    Parkinsonism & related disorders, 2019, Volume: 58

    Topics: Aged; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Indans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple System Atrophy; Neuroprotective Agents; Prospective Studies

2019
Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial.
    The Lancet. Neurology, 2015, Volume: 14, Issue:2

    Topics: Aged; Double-Blind Method; Female; Humans; Indans; Male; Middle Aged; Multiple System Atrophy; Neuroprotective Agents; Parkinsonian Disorders; Treatment Outcome

2015
Minimally clinically important decline in the parkinsonian variant of multiple system atrophy.
    Movement disorders : official journal of the Movement Disorder Society, 2016, Volume: 31, Issue:10

    Topics: Aged; Female; Humans; Indans; Male; Middle Aged; Minimal Clinically Important Difference; Multiple System Atrophy; Neuroprotective Agents; Parkinsonian Disorders; Severity of Illness Index

2016

Other Studies

2 other study(ies) available for rasagiline and Multiple System Atrophy Syndrome

ArticleYear
Clinical trials for multiple system atrophy.
    The Lancet. Neurology, 2015, Volume: 14, Issue:2

    Topics: Female; Humans; Indans; Male; Multiple System Atrophy; Neuroprotective Agents; Parkinsonian Disorders

2015
Rasagiline is neuroprotective in a transgenic model of multiple system atrophy.
    Experimental neurology, 2008, Volume: 210, Issue:2

    Topics: alpha-Synuclein; Analysis of Variance; Animals; Behavior, Animal; Brain; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dose-Response Relationship, Drug; Indans; Mice; Mice, Transgenic; Motor Activity; Multiple System Atrophy; Myelin Proteolipid Protein; Neurons; Neuroprotective Agents; Nitro Compounds; Propionates; Psychomotor Performance; Tyrosine 3-Monooxygenase

2008